Ask AI
Frontline Therapy in Hodgkin Lymphoma

CE / CME

Transforming Frontline Therapy in Hodgkin Lymphoma: Advancing Personalized Strategies for Optimal Outcomes

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: July 02, 2025

Expiration: December 31, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

How confident are you in applying new treatment options to frontline classical Hodgkin lymphoma?

2.

Which frontline treatment would you recommend for a 28-yr-old woman with advanced-stage cHL, a history of inflammatory bowel disease, and strong concerns about preserving fertility?

3.

Patient Case: 69-Yr-Old Man With Newly Diagnosed HL



  • A 69-yr-old man is newly diagnosed with stage IIIB cHL

  • ECOG performance status of 1

  • History of mild chronic obstructive pulmonary disease

  • Ejection fraction 60%

  • No contraindications to immunotherapy, but is at increased risk for bleomycin-induced pulmonary toxicity

  • He expresses a preference to avoid regimens with high long-term toxicity risk and is open to novel therapies

Which frontline treatment option would you choose for this patient?

4.

The first-line treatment regimen Bv-AVE-PC (AHOD1331 trial) would be most appropriate for which pediatric patient high-risk group?